Gilead Sciences, Inc. $GILD Holdings Decreased by GRIMES & Co WEALTH MANAGEMENT LLC

Key Points

• GRIMES & Co WEALTH MANAGEMENT LLC cut its Gilead stake by 6.1% to 150,368 shares (about $18.46M), while institutional investors still own roughly 83.7% of the company.
• Gilead beat Q1 expectations—EPS $2.03 vs. $1.91 and revenue $6.96B vs. $6.91B—and management raised its 2026 sales forecast, indicating underlying revenue strength.
• Despite the top‑line strength, Gilead withdrew prior profit guidance and now expects an adjusted FY2026 loss of $1.05 to $0.65 per share, citing acquisition‑related charges and financing costs that weigh on earnings.

GRIMES & Co WEALTH MANAGEMENT LLC reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 6.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 150,368 shares of the biopharmaceutical company's stock after selling 9,777 shares during the quarter. GRIMES & Co WEALTH MANAGEMENT LLC's holdings in Gilead Sciences were worth $18,456,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Ares Financial Consulting LLC bought a new stake in shares of Gilead Sciences during the fourth quarter valued at about $28,000. Corundum Trust Company INC bought a new stake in shares of Gilead Sciences during the third quarter valued at about $26,000. Financial Consulate Inc. raised its stake in shares of Gilead Sciences by 85.8% during the fourth quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company's stock valued at $29,000 after purchasing an additional 109 shares in the last quarter. North Star Investment Management Corp. raised its stake in shares of Gilead Sciences by 54.8% during the fourth quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 86 shares in the last quarter. Finally, BOCHK Asset Management Ltd bought a new stake in shares of Gilead Sciences during the fourth quarter valued at about $31,000. 83.67% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on GILD. Needham & Company LLC restated a "buy" rating and set a $170.00 price objective on shares of Gilead Sciences in a research note on Monday, February 23rd. Scotiabank boosted their price target on shares of Gilead Sciences from $140.00 to $177.00 and gave the stock a "sector outperform" rating in a research report on Wednesday, February 11th. Barclays initiated coverage on shares of Gilead Sciences in a research report on Friday, February 20th. They issued an "equal weight" rating and a $155.00 price target on the stock. Bank of America set a $162.00 price target on shares of Gilead Sciences and gave the stock a "buy" rating in a research report on Wednesday, February 11th. Finally, Royal Bank Of Canada boosted their price target on shares of Gilead Sciences from $118.00 to $123.00 and gave the stock a "sector perform" rating in a research report on Tuesday, April 7th. Twenty-four analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, Gilead Sciences currently has a consensus rating of "Moderate Buy" and a consensus target price of $157.35.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q1 results beat estimates — Gilead reported $2.03 EPS vs. a $1.89 consensus and revenue of $6.96B vs. ~$6.91B, showing underlying quarter strength. Gilead Sciences (GILD) Tops Q1 Earnings and Revenue Estimates
• Positive Sentiment: Management raised its 2026 sales forecast, indicating revenue strength despite other headwinds. Gilead raises 2026 sales forecast, cuts profit outlook due to acquisitions
• Neutral Sentiment: Full‑year revenue guidance was issued at roughly $30.0–30.4B, near analyst consensus — so sales expectations are roughly intact even as profit guidance shifted. Gilead Press Release / Slide Deck
• Neutral Sentiment: Shareholders approved the board and executive pay plans at the 2026 meeting — governance items cleared without disruption. Gilead Shareholders Back Board, Pay Plans at 2026 Meeting
• Negative Sentiment: Company withdrew prior profit guidance and now expects an adjusted FY2026 loss of $1.05 to $0.65 per share (versus prior ~$8.45–8.85 outlook and analyst expectations near $8.65), a dramatic revision that hits valuation and investor confidence. Gilead Sciences Expects Loss This Year on Acquired R&D Expenses
• Negative Sentiment: Management attributes the profit swing to acquisition‑related charges and financing costs tied to recent deals — these one‑time and financing items meaningfully depress reported earnings for the year. Gilead raises 2026 sales forecast, cuts profit outlook due to acquisitions

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 3,000 shares of the business's stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $140.96, for a total value of $422,880.00. Following the completion of the sale, the chief financial officer owned 176,191 shares of the company's stock, valued at approximately $24,835,883.36. The trade was a 1.67% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction that occurred on Tuesday, April 28th. The shares were sold at an average price of $129.16, for a total value of $1,291,600.00. Following the completion of the sale, the chief executive officer directly owned 632,567 shares of the company's stock, valued at approximately $81,702,353.72. The trade was a 1.56% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 63,000 shares of company stock valued at $9,238,250. 0.30% of the stock is owned by corporate insiders.

Gilead Sciences Trading Down 1.6%

Shares of GILD opened at $134.06 on Friday. The business's 50-day moving average price is $139.59 and its 200 day moving average price is $132.87. The stock has a market capitalization of $166.40 billion, a P/E ratio of 19.80, a P/E/G ratio of 1.80 and a beta of 0.31. Gilead Sciences, Inc. has a 1-year low of $95.29 and a 1-year high of $157.29. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 earnings per share for the quarter, topping analysts' consensus estimates of $1.91 by $0.12. The firm had revenue of $6.96 billion for the quarter, compared to analysts' expectations of $6.91 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.Gilead Sciences's revenue was up 4.4% on a year-over-year basis. During the same quarter last year, the business posted $1.81 EPS. Gilead Sciences has set its FY 2026 guidance at -1.050--0.650 EPS. Analysts expect that Gilead Sciences, Inc. will post 8.62 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, June 29th. Investors of record on Monday, June 15th will be paid a $0.82 dividend. The ex-dividend date of this dividend is Monday, June 15th. This represents a $3.28 dividend on an annualized basis and a yield of 2.4%. Gilead Sciences's dividend payout ratio (DPR) is currently 48.45%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.